Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2013 May;143(5):1478-1479.
doi: 10.1378/chest.12-1604.

An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor

Nicholas G Wysham  1 , Donald R Sullivan  2 , Gopal Allada  3
Affiliations
Case Reports

An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor

Nicholas G Wysham et al. Chest. 2013 May.

Abstract

We report a case of Cryptococcus neoformans pneumonia in a patient taking ruxolitinib, a janus kinase 1,2 inhibitor approved for the treatment of myelofibrosis. We hypothesize that ruxolitinib contributed to this infection through its effects on cell-mediated immunity. Clinicians should be aware of the potential for intracellular or opportunistic infections associated with this novel drug class.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Noncontrast CT image of the chest demonstrating multifocal consolidations with surrounding ground glass opacities in a bronchovascular distribution and upper-lobe predominance.
See this image and copyright information in PMC

References

    1. Verstovsek S, Mesa RA, Gotlib J. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799–807. - PMC - PubMed
    1. Garber K. Pfizer's JAK inhibitor sails through phase 3 in rheumatoid arthritis. Nat Biotechnol. 2011;29(6):467–468. - PubMed
    1. Sandborn WJ, Ghosh S, Panes J, Study A3921063 Investigators Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med. 2012;367(7):616–624. - PubMed
    1. Tefferi A. Challenges facing JAK inhibitor therapy for myeloproliferative neoplasms. N Engl J Med. 2012;366(9):844–846. - PubMed
    1. Voelz K, May RC. Cryptococcal interactions with the host immune system. Eukaryot Cell. 2010;9(6):835–846. - PMC - PubMed

Publication types

MeSH terms